{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=98",
    "query": {
      "intervention": "Saline (Placebo Control)",
      "page": 98
    },
    "page_size": 10
  },
  "pagination": {
    "page": 98,
    "page_size": 10,
    "total_count": 3537,
    "total_pages": 354,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=99&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=97&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T20:18:05.579Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01224015",
      "title": "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Facial Rhytides",
        "Crow's Feet Lines",
        "Glabellar Lines"
      ],
      "interventions": [
        {
          "name": "normal saline",
          "type": "DRUG"
        },
        {
          "name": "onabotulinumtoxinA 44 U",
          "type": "BIOLOGICAL"
        },
        {
          "name": "onabotulinumtoxinA 24 U",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 684,
      "start_date": "2011-05",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2014-02-25",
      "last_synced_at": "2026-11-18T20:18:05.579Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01224015"
    },
    {
      "nct_id": "NCT06178991",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Influenza and COVID-19 Combination A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza and COVID-19 Combination B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 8795,
      "start_date": "2023-12-20",
      "completion_date": "2024-11-26",
      "has_results": true,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-11-18T20:18:05.579Z",
      "location_count": 106,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06178991"
    },
    {
      "nct_id": "NCT06365762",
      "title": "The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age Related Cataracts"
      ],
      "interventions": [
        {
          "name": "EDTA Ophthalmic Solution 2.6%",
          "type": "DRUG"
        },
        {
          "name": "EDTA Ophthalmic Solution 1.3%",
          "type": "DRUG"
        },
        {
          "name": "Saline Solution (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Livionex Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2006-01-01",
      "completion_date": "2007-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-04-16",
      "last_synced_at": "2026-11-18T20:18:05.579Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Overland Park, Kansas • Lutherville, Maryland + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06365762"
    },
    {
      "nct_id": "NCT01840774",
      "title": "Modifying Virtual Reality Analgesia With Low-Dose Pain Medication",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Virtual Reality Therapy"
      ],
      "interventions": [
        {
          "name": "Low-dose pain medication (Ketalar) and saline placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2013-04",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2013-04-26",
      "last_synced_at": "2026-11-18T20:18:05.579Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01840774"
    },
    {
      "nct_id": "NCT00534313",
      "title": "Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2007-11",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-11-18T20:18:05.579Z",
      "location_count": 19,
      "location_summary": "Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00534313"
    },
    {
      "nct_id": "NCT07219459",
      "title": "Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Unresectable or Metastatic Hepatocellular Carcinoma",
        "Child-Pugh A Hepatocellular Carcinoma",
        "Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound"
      ],
      "interventions": [
        {
          "name": "Visugromab RDE (recommended dose for expansion)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo Saline Infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "CatalYm GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 104,
      "start_date": "2026-03-19",
      "completion_date": "2031-09",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-18T20:18:05.579Z",
      "location_count": 7,
      "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 4 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219459"
    },
    {
      "nct_id": "NCT05648110",
      "title": "Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19, SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "AZD5156 (Parent study Sentinel Safety Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Parent study Sentinel Safety Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EVUSHELD™ (Parent study Main Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD3152 (Parent study Main Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Parent study Main Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD3152 (Sub-study)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 - EVUSHELD™ (Sub-study)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "12 Years to 130 Years"
      },
      "enrollment_count": 3882,
      "start_date": "2022-12-16",
      "completion_date": "2025-02-11",
      "has_results": true,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-11-18T20:18:05.579Z",
      "location_count": 130,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05648110"
    },
    {
      "nct_id": "NCT00752297",
      "title": "Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Rhytides"
      ],
      "interventions": [
        {
          "name": "Preservative-free Saline",
          "type": "DRUG"
        },
        {
          "name": "Mentor Purified Toxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mentor Worldwide, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 402,
      "start_date": "2007-06",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2011-09-12",
      "last_synced_at": "2026-11-18T20:18:05.579Z",
      "location_count": 1,
      "location_summary": "Santa Barbara, California",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00752297"
    },
    {
      "nct_id": "NCT06451120",
      "title": "Platelet Rich Plasma Injections In Young And Old Human Subjects",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis",
        "Articular Cartilage",
        "Musculoskeletal Disorders"
      ],
      "interventions": [
        {
          "name": "Platelet-Rich Plasma (PRP) Injections",
          "type": "DRUG"
        },
        {
          "name": "Centrifuge",
          "type": "DEVICE"
        },
        {
          "name": "Control saline injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-06-01",
      "completion_date": "2027-02-16",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-18T20:18:05.579Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06451120"
    },
    {
      "nct_id": "NCT03985982",
      "title": "Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Frown Lines"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Croma-Pharma GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 410,
      "start_date": "2019-04-29",
      "completion_date": "2020-12-22",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-11-18T20:18:05.579Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03985982"
    }
  ]
}